Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/cap.2015.0202 | DOI Listing |
United European Gastroenterol J
January 2025
Second Department of Internal Medicine and Gastroenterology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Introduction: Chronic nausea and vomiting are symptoms of a wide range of gastrointestinal and non-gastrointestinal conditions. Diagnosis can be challenging and requires a systematic and well-structured approach. If the initial investigation for structural, toxic and metabolic disorders is negative, digestive motility and gut-brain interaction disorders should be assessed.
View Article and Find Full Text PDFBreast
December 2024
Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Mexico; MILC, Médicos e Investigadores en la Lucha contra el Cáncer de Mama, Ciudad De México, Mexico. Electronic address:
Introduction: Cancer treatments have a detrimental impact on the quality of life (QoL) of young women with breast cancer (YWBC). Research exploring QoL trajectories has been mostly centered on postmenopausal women. Here we report longitudinal changes across all QoL domains and associated factors in YWBC.
View Article and Find Full Text PDFKorean J Anesthesiol
January 2025
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi 13620, Republic of Korea.
Background: Remimazolam is a novel short-acting benzodiazepine. This study compared the effects of remimazolam and propofol on cognitive function in adult patients after surgery or other procedures.
Methods: We searched electronic databases, including PubMed, EMBASE, CENTRAL, Web of Science, and SCOPUS, for relevant studies.
Nat Commun
January 2025
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC). This study consisted of two parts. In part 1, the 3 + 3 design was used to investigate three dose levels of HE072 (50, 70 and 90 mg/m).
View Article and Find Full Text PDFJ Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!